Earnings Releases·Nov 12, 2026, 4:15 PM ET

Azitra, Inc. — Q3 2026 Earnings Summary

Net loss widened to $3.0 million for Q3 2026 from $2.8 million in the prior year period, driven by a $100,000 increase in R&D expenses, while cash and cash equivalents rose to $3.8 million from $2.1 million at year-end 2025.
ATR-04 Phase 1/2 trial Cohort 1 completed with safety committee approval to proceed to Cohort 2 (24 patients), and the program received FDA Fast Track designation for cancer treatment-associated rash.
ATR-COSF ex vivo data showed a ~50% reduction in fine lines after 48 hours; initial first-in-human cosmetic study results are anticipated by year-end 2026, with topline data for ATR-04 Cohort 1 expected in Q4 2026.
Management identifies the remainder of 2026 as a "defining period," noting potential follow-on financing of $5.25 million to $10.5 million for existing institutional investors contingent on ATR-COSF results.